Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy

J.L. Kuiper; I. Bahce; C. Voorhoeve; M. Yaqub; D.A.M. Heideman; E. Thunnissen; M.A. Paul; P.E. Postmus; N.H. Hendrikse; E.F. Smit

doi:https://doi.org/10.2217/PME.14.64

Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy

J.L. Kuiper, I. Bahce, C. Voorhoeve, M. Yaqub, D.A.M. Heideman, E. Thunnissen, M.A. Paul, P.E. Postmus, N.H. Hendrikse, E.F. Smit

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

Tumor heterogeneity plays an important role in the development of treatment-resistance, especially in the current era of targeted therapies. Although tumor heterogeneity is a widely recognized phenomenon, it is at present unclear how this knowledge should be incorporated into daily clinical practice. In this report, we describe an innovative nuclear imaging method that may play a role in detecting tumor heterogeneity in the future.

Original language	English
Pages (from-to)	63-66
Number of pages	4
Journal	Personalized Medicine
Volume	12
Issue number	2
DOIs	https://doi.org/10.2217/PME.14.64 https://doi.org/10.2217/pme.14.64
Publication status	Published - Mar 2015

Access to Document

Cite this

Kuiper, J. L., Bahce, I., Voorhoeve, C., Yaqub, M., Heideman, D. A. M., Thunnissen, E., Paul, M. A., Postmus, P. E., Hendrikse, N. H., & Smit, E. F. (2015). Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. Personalized Medicine, 12(2), 63-66. https://doi.org/10.2217/PME.14.64, https://doi.org/10.2217/pme.14.64

@article{f3f0163dea654af591a11b17bfcdbb5c,

title = "Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy",

abstract = "Tumor heterogeneity plays an important role in the development of treatment-resistance, especially in the current era of targeted therapies. Although tumor heterogeneity is a widely recognized phenomenon, it is at present unclear how this knowledge should be incorporated into daily clinical practice. In this report, we describe an innovative nuclear imaging method that may play a role in detecting tumor heterogeneity in the future.",

author = "J.L. Kuiper and I. Bahce and C. Voorhoeve and M. Yaqub and D.A.M. Heideman and E. Thunnissen and M.A. Paul and P.E. Postmus and N.H. Hendrikse and E.F. Smit",

year = "2015",

month = mar,

doi = "https://doi.org/10.2217/PME.14.64",

language = "English",

volume = "12",

pages = "63--66",

journal = "Personalized Medicine",

issn = "1741-0541",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy

AU - Kuiper, J.L.

AU - Bahce, I.

AU - Voorhoeve, C.

AU - Yaqub, M.

AU - Heideman, D.A.M.

AU - Thunnissen, E.

AU - Paul, M.A.

AU - Postmus, P.E.

AU - Hendrikse, N.H.

AU - Smit, E.F.

PY - 2015/3

Y1 - 2015/3

N2 - Tumor heterogeneity plays an important role in the development of treatment-resistance, especially in the current era of targeted therapies. Although tumor heterogeneity is a widely recognized phenomenon, it is at present unclear how this knowledge should be incorporated into daily clinical practice. In this report, we describe an innovative nuclear imaging method that may play a role in detecting tumor heterogeneity in the future.

AB - Tumor heterogeneity plays an important role in the development of treatment-resistance, especially in the current era of targeted therapies. Although tumor heterogeneity is a widely recognized phenomenon, it is at present unclear how this knowledge should be incorporated into daily clinical practice. In this report, we describe an innovative nuclear imaging method that may play a role in detecting tumor heterogeneity in the future.

U2 - https://doi.org/10.2217/PME.14.64

DO - https://doi.org/10.2217/PME.14.64

M3 - Article

C2 - 29754538

SN - 1741-0541

VL - 12

SP - 63

EP - 66

JO - Personalized Medicine

JF - Personalized Medicine

IS - 2

ER -